The body of research on nirmatrelvir-ritonavir demonstrates a plethora of benefits in the treatment of COVID-19, and authors of a recent study identified more advantages to administering the treatment ...
Please provide your email address to receive an email when new articles are posted on . As the COVID-19 pandemic heads into its 4th year, it is a good time to reflect on strides made for those with ...
Meaningful reduction in symptoms seen for some taking an extended course outside of the context of an acute infection. HealthDay News — Extended-course nirmatrelvir/ritonavir yields a meaningful ...
Nirmatrelvir-ritonavir use was associated with substantially lower rates of COVID-19-related hospitalization among high-risk outpatients.
Nirmatrelvir-ritonavir was beneficial for COVID-19 management in patients with chronic kidney disease or kidney failure, significantly reducing the risk of mortality and hospital admission. Paxlovid ® ...
Study shows ritonavir-boosted nirmatrelvir remains effective against new omicron variants in the U.S
In a study published in The Lancet Regional Health – Americas, researchers from the United States of America (USA) assessed the effectiveness of ritonavir-boosted nirmatrelvir (NMV-r) against Omicron ...
Most measures to reduce household spread of Covid-19 have shown varying effectiveness. Whether postexposure prophylaxis with oral nirmatrelvir–ritonavir could help reduce transmission is unknown. New ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback